Antioxidantes da dieta como inibidores da nefrotoxicidade induzida pelo antitumoral cisplatina

Antunes, Lusânia Maria Greggi; Bianchi, María de Lourdes Pires

doi:10.1590/s1415-52732004000100010

Cited by 16 publications

(13 citation statements)

References 22 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The renal toxicity observed in this present study is related to nephrotoxic and/ or vesical toxic effect of the drug, as reported by Costa et al (2004). According to Antunes & Bianchi (2004), the nephrotoxicity is one of the main side-effects of therapy with cisplatin, an antineoplastic drug as well as cyclophosphamide. Based on employed methodology and obtained results, it is possible to conclude that cyclophosphamide leads to a decrease in body weight and testicles weight, in all administered concentrations, at doses of 150, 200 and 250 mg.kg -1 ; it decreases also epididymides and liver weights; alters the morphology of spermatozoids compromising so the fertilization; presents toxicity for liver and kidneys and, in addition, decreases fetal viability increasing so the reabsorption rate; however, this chemotherapeutic didn't cause significant malformations in the offspring of treated males.…”

Section: Discussionsupporting

confidence: 76%

Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice

Kanno

Sensiate

Paula

et al. 2009

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The cyclophosphamide is used in cancer treatment. The aim of this study was evaluating the effect of different doses of this drug on male mice reproductive parameters. The cyclophosphamide was administered in the doses 100, 150, 200 e 250 mg.kg -1 , intraperitoneal route, for six weeks. As a result, it was observed a decrease in body mass and a decrease in testicles and kidney's weight, in all animals treated with cyclophosphamide. Only the groups that received the doses 100, 150 mg.kg -1 of cyclophosphamide were able to fertilize their females. There was higher incidence of post-implantation losses, reabsorptions and decrease in fetal viability in the group that received the dose of 150 mg.kg . Based on the methodology used and results obtained, it was concluded that the cyclophosphamide was toxic, considering the decrease in animal's body mass and testicle's weight; promoted hepatotoxicity and nephrotoxic effect; influenced in the animals spermatogenesis taking them to infertility and/or subfertility; decreased fetal viability, despite it didn't cause significant malformations in the offspring.Uniterms: Cyclophosphamide/effects. Cyclophosphamide/toxicity. Spermatogenesis/experimental study. Chemotherapeutics/adverse effects. Fertility/experimental study.A ciclofosfamida é utilizada no tratamento de câncer. Este estudo visa avaliar os efeitos das diferentes doses do fármaco nos parâmetros reprodutivos de camundongos machos. A ciclofosfamida foi administrada nas doses de 100, 150, 200 e 250 mg kg -1 , via intraperitoneal por seis semanas. Como resultado observou-se diminuição de massa corporal, redução no peso de testículos e rins em todos os animais tratados com a ciclofosfamida. Apenas os grupos que receberam as doses de 100 e 150 mg kg -1 do quimioterápico foram capazes de fertilizar as fêmeas. Houve maior incidência de perdas pós-implantação, reabsorção e diminuição da viabilidade fetal no grupo que recebeu a dose de 150 mg kg -1 . Observou-se redução nos pesos dos epidídimos e fígado dos animais tratados com as doses de 150, 200 e 250 mg kg -1 . Espermatozóides anômalos foram encontrados nas doses de 200 e 250mg kg -1 . Com base na metodologia empregada e nos resultados obtidos, conclui-se que a ciclofosfamida foi tóxica considerando-se a redução de massa corporal e o peso dos testículos dos animais; promoveu hepatotoxicidade e efeito nefrotóxico; influenciou na espermatogênese dos animais de forma a levá-los a um estado de infertilidade e/ou subfertilidade; diminuiu viabilidade fetal, entretanto não causou malformações significativas na prole.Unitermos: Ciclofosfamida/efeitos. Ciclofosfamida/toxicidade. Espermatogênese/estudo experimental. Quimioterápicos/efeitos adversos. Fertilidade/ estudo experimental.

show abstract

Section: Discussionsupporting

confidence: 76%

Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice

Kanno

Sensiate

Paula

et al. 2009

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…It can react with many cellular structures and molecules, such as membranes, proteins, and RNA, but its specific target is DNA. Administration of antioxidant agents, which can sequester free radicals from oxygen, results in effective protection against the oxidative damage induced by cisplatin (Antunes and Bianchi, 2004).…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have provided evidence that chemotherapy side effects are mediated by free radicals both in vivo and in vitro (Antunes and Bianchi, 2004). Weijl et al (1998) found that chemotherapy with cisplatin reduces the patient's plasma antioxidant levels, demonstrating that free radical production occurs during treatment.…”

Section: Discussionmentioning

confidence: 99%

Antigenotoxic and antimutagenic effects of glutamine supplementation on mice treated with cisplatin

Pesarini¹,

Sg²,

Ap³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We evaluated the effects of glutamine on clastogenic and genotoxic damage prevention caused by the administration of cisplatin. 4821©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (3): 4820-4830 (2014) Glutamine prevents DNA damage Forty Swiss mice were divided into 8 experimental groups: G1 and G2, which were control groups; G3, G4, and G5, which were administered [2 doses of glutamine (orally)] separated by a 24-h period (150, 300, and 600 mg/kg, respectively), and a dose of phosphate-buffered saline by intraperitoneal injection; G6, G7, and G8, which were treated in the same manner as the previous groups, but received cisplatin rather than phosphate-buffered saline. The antimutagenicity groups showed damage reduction percentages of 79.05, 80.00, and 94.27% at the time point T1, 53.18, 67.05, and 64.74 at time point T2 for the 150, 300, and 600 mg/kg doses of glutamine, respectively. Antigenotoxic activity was evident for all 3 doses with damage reduction percentages of 115.05, 119.06, and 114.38 for the doses of glutamine of 150, 300, and 600 mg/ kg, respectively. These results suggest that further studies are needed to confirm the clastogenic activity of glutamine. However, our results may lead to rational strategies for supplementation of this antioxidant as an adjuvant in cancer treatment or for preventing genomic lesions.

show abstract

“…La cisplatina es uno de los agentes antineoplásicos que ha presentado mayor potencial terapéutico en gran variedad de neoplasias humanas y de animales, principalmente en el tratamiento de los tumores de testículo, ovario, melanomas malignos y tumores de cabeza y cuello. Sin embargo su uso se ha limitado debido a sus efectos colaterales (1).…”

Section: Introductionunclassified

Evaluación del hemograma en caninos sanos sometidos a la administracion de cisplatina

O¹,

Daleck

Castro

2010

Rev MVZ Córdoba

View full text Add to dashboard Cite

RESUMENObjetivo. Evaluar los valores medios del hemograma en perros sanos durante la quimioterapia con cisplatina. Materiales y métodos. Se evaluaron los parámetros del hemograma de ocho caninos sanos sometidos a terapia con cisplatina, distribuidos en dos grupos. A los perros del grupo uno se les administró cisplatina (70 mg/m², i.v.) y para prevenir la nefrotoxicidad recibieron suero fisiológico al 0.9% (25mL/kg/h, i.v.). Los animales del grupo dos no recibieron cisplatina. Resultados. El hemograma de los perros del grupo uno no mostró diferencia significativa (p>0.05) con respecto al de los animales del grupo dos. Conclusiones. Los datos obtenidos indicaron que el protocolo con cisplastina no alteró significativamente los valores medios del hemograma y el número de sesiones de quimioterapia aumenta el riesgo de disminución de los valores del hemograma.Palabras clave: Cisplatina, quimioterapia, hemograma, hemoglobina, leucocitos, perros. ABSTRACTObjective. To evaluate the average values of the hemogram test in healthy dogs during chemotherapy with cisplatin. Materials and methods. The hemogram parameters of eight healthy canines, which underwent therapy with cisplatin, were evaluated. These canines were divided into two groups. The dogs in the first group were given cisplatin (70mg/m², i.v.) and to prevent kidney poisoning they were given physiological serum at 0.9% (25mL/ kg/h, i.v.). The dogs in group two were not given cisplatin. Results. The hemogram of the dogs in the first group did not show any significant difference (p>0.05) as compared to the dogs in group 2.Conclusions. The data obtained indicate the protocol used with cisplatine does not significantly alter the average values of the hemogram test and the number of chemotherapy sessions increases the risk of diminishing the values of the hemogram test.

show abstract

Antioxidantes da dieta como inibidores da nefrotoxicidade induzida pelo antitumoral cisplatina

Cited by 16 publications

References 22 publications

Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice

Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice

Antigenotoxic and antimutagenic effects of glutamine supplementation on mice treated with cisplatin

Evaluación del hemograma en caninos sanos sometidos a la administracion de cisplatina

Contact Info

Product

Resources

About